These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22180724)

  • 41. The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patients.
    Bokharaei-Salim F; Salehi-Vaziri M; Sadeghi F; Esghaei M; Monavari SH; Alavian SM; Fakhim S; Keyvani H
    Hepat Mon; 2016 May; 16(5):e35597. PubMed ID: 27313635
    [TBL] [Abstract][Full Text] [Related]  

  • 42. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.
    Meissner EG; Bon D; Prokunina-Olsson L; Tang W; Masur H; O'Brien TR; Herrmann E; Kottilil S; Osinusi A
    J Infect Dis; 2014 Jun; 209(11):1700-4. PubMed ID: 24367041
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
    Pawlotsky JM; Flisiak R; Sarin SK; Rasenack J; Piratvisuth T; Chuang WL; Peng CY; Foster GR; Shah S; Wedemeyer H; Hézode C; Zhang W; Wong KA; Li B; Avila C; Naoumov NV;
    Hepatology; 2015 Oct; 62(4):1013-23. PubMed ID: 26118427
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
    Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
    Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
    Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.
    Naik GS; Tyagi MG
    J Clin Exp Hepatol; 2012 Mar; 2(1):42-54. PubMed ID: 25755405
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy.
    Ghanem SE; Elsabaawy M; Shebl N; Abdelsameea E; Othman W; El-Bassal FI; Elgedawy GA; Elsabaawy DM; Helal ML
    Expert Rev Anti Infect Ther; 2020 Sep; 18(9):947-954. PubMed ID: 32419526
    [No Abstract]   [Full Text] [Related]  

  • 49. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.
    El-Shamy A; Shoji I; Kim SR; Ide Y; Imoto S; Deng L; Yoon S; Fujisawa T; Tani S; Yano Y; Seo Y; Azuma T; Hotta H
    PLoS One; 2012; 7(2):e30513. PubMed ID: 22319571
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
    Hayashi K; Katano Y; Kuzuya T; Tachi Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Med Virol; 2012 Mar; 84(3):438-44. PubMed ID: 22246829
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment.
    Dash S; Aydin Y; Widmer KE; Nayak L
    J Hepatocell Carcinoma; 2020; 7():45-76. PubMed ID: 32346535
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents.
    Kamal SM
    Hepat Med; 2014; 6():61-77. PubMed ID: 25114601
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.
    Linas BP; Barter DM; Leff JA; DiLorenzo M; Schackman BR; Horsburgh CR; Assoumou SA; Salomon JA; Weinstein MC; Kim AY; Freedberg KA
    AIDS; 2014 Jan; 28(3):365-76. PubMed ID: 24670522
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
    Jacobson I; Zeuzem S; Flisiak R; Knysz B; Lueth S; Zarebska-Michaluk D; Janczewska E; Ferenci P; Diago M; Zignego AL; Safadi R; Baruch Y; Abdurakhmanov D; Shafran S; Thabut D; Bruck R; Gadano A; Thompson AJ; Kopit J; McPhee F; Michener T; Hughes EA; Yin PD; Noviello S
    World J Gastroenterol; 2016 Mar; 22(12):3418-31. PubMed ID: 27022224
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection.
    Neukam K; Caruz A; Rivero-Juárez A; Barreiro P; Merino D; Real LM; Herrero R; Camacho A; Soriano V; Di Lello FA; Macías J; Rivero A; Pineda JA
    AIDS; 2013 Nov; 27(17):2715-24. PubMed ID: 23842134
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Host genetics.
    Macías J; Vispo E; Pineda JA; Soriano V
    Curr Opin HIV AIDS; 2011 Nov; 6(6):491-500. PubMed ID: 21918436
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy.
    Yuan H; Adams-Huet B; Petersen T; Attar N; Lee WM; Jain MK
    J Med Virol; 2012 Dec; 84(12):1913-9. PubMed ID: 23080496
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Synopsis of Hepatitis C Virus Treatments and Future Perspectives.
    Medina C; García AH; Crespo FI; Toro FI; Mayora SJ; De Sanctis JB
    Curr Issues Mol Biol; 2023 Oct; 45(10):8255-8276. PubMed ID: 37886964
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.
    Hsu CS; Hsu SJ; Chen HC; Tseng TC; Liu CH; Niu WF; Jeng J; Liu CJ; Lai MY; Chen PJ; Kao JH; Chen DS
    Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3719-24. PubMed ID: 21321200
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.
    de Castellarnau M; Aparicio E; Parera M; Franco S; Tural C; Clotet B; Martínez MA
    PLoS One; 2012; 7(2):e31016. PubMed ID: 22328925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.